Science & Programs
Resverlogix is a late-stage clinical biotechnology company dedicated to improving the lives of patients with chronic illnesses and providing value-based health solutions to key partners.
The world leader in a new class of drugs designed to regulate disease-associated epigenetics.
BETonMACE – a global Phase 3 clinical trial with the most advanced epigenetic drug outside of oncology.
Providing novel science, clinical and value-based health solutions to key stakeholders, including payer groups.
Resverlogix (TSX: RVX), founded in 2001 by Donald McCaffrey and Norman Wong, focuses on the development of therapeutics for disease states with high unmet medical need.
- : Resverlogix Announces Commencement of Patient Enrollment and Dosing in a Phase 2b Trial for a Promising Canadian-Developed COVID-19 Treatment
- : Resverlogix Announces Corporate Update Webcast and Conference Call
- : Resverlogix Enters into a Cooperation Agreement with the Supreme Council of the Arab-African Economy to Support the Development of Apabetalone for COVID-19 Patients